Collegium Pharmaceutical, Inc (COLL) stock
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3045% below fair value
$24.81+0.34 (+1.39%)
Close on Nov 11, 2026Market cap $807.71MP/E 24.8Yield –
Collegium Pharmaceutical cash
Cash and short-term investments held at the end of each period.
Collegium Pharmaceutical's cash was $144.80M at Sep 30, 2026. For fiscal 2025 it was $386.68M, up 104.8% from the year before. Over ten years it grew 15.0% a year on average. The highest annual figure on record is $386.68M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $386.68M | +104.8% |
| FY2024 | Dec 31, 2024 | $188.81M | -39.2% |
| FY2023 | Dec 31, 2023 | $310.55M | +76.2% |
| FY2022 | Dec 31, 2022 | $176.24M | -6.7% |
| FY2021 | Dec 31, 2021 | $188.97M | +7.0% |
| FY2020 | Dec 31, 2020 | $176.66M | +3.9% |
| FY2019 | Dec 31, 2019 | $170.02M | +15.9% |
| FY2018 | Dec 31, 2018 | $146.63M | +23.4% |
| FY2017 | Dec 31, 2017 | $118.79M | -22.5% |
| FY2016 | Dec 31, 2016 | $153.32M | +60.1% |
| FY2015 | Dec 31, 2015 | $95.79M | +5762.5% |
| FY2014 | Dec 31, 2014 | $1.63M | -78.4% |
| FY2013 | Dec 31, 2013 | $7.55M | -36.7% |
| FY2012 | Dec 31, 2012 | $11.94M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $144.80M | -49.3% |
| Q2 FY2026 | Jun 30, 2026 | $129.47M | -41.7% |
| Q1 FY2026 | Mar 31, 2026 | $421.75M | +113.2% |
| Q4 FY2025 | Dec 31, 2025 | $386.68M | +104.8% |
| Q3 FY2025 | Sep 30, 2025 | $285.86M | +138.3% |
| Q2 FY2025 | Jun 30, 2025 | $222.15M | -18.2% |
| Q1 FY2025 | Mar 31, 2025 | $197.77M | -37.8% |
| Q4 FY2024 | Dec 31, 2024 | $188.81M | -39.2% |
| Q3 FY2024 | Sep 30, 2024 | $119.96M | -60.6% |
| Q2 FY2024 | Jun 30, 2024 | $271.63M | -16.5% |
| Q1 FY2024 | Mar 31, 2024 | $318.05M | +18.0% |
| Q4 FY2023 | Dec 31, 2023 | $310.55M | +76.2% |
| Q3 FY2023 | Sep 30, 2023 | $304.57M | +127.1% |
| Q2 FY2023 | Jun 30, 2023 | $325.47M | +165.2% |
| Q1 FY2023 | Mar 31, 2023 | $269.48M | +152.6% |
| Q4 FY2022 | Dec 31, 2022 | $176.24M | -6.7% |
| Q3 FY2022 | Sep 30, 2022 | $134.13M | -30.6% |
| Q2 FY2022 | Jun 30, 2022 | $122.72M | -39.5% |
| Q1 FY2022 | Mar 31, 2022 | $106.70M | -41.6% |
| Q4 FY2021 | Dec 31, 2021 | $188.97M | +7.0% |
| Q3 FY2021 | Sep 30, 2021 | $193.24M | +16.8% |
| Q2 FY2021 | Jun 30, 2021 | $202.77M | +39.2% |
| Q1 FY2021 | Mar 31, 2021 | $182.79M | +57.3% |
| Q4 FY2020 | Dec 31, 2020 | $176.66M | +3.9% |
| Q3 FY2020 | Sep 30, 2020 | $165.42M | +7.5% |
| Q2 FY2020 | Jun 30, 2020 | $145.68M | -2.0% |
| Q1 FY2020 | Mar 31, 2020 | $116.18M | -13.9% |
| Q4 FY2019 | Dec 31, 2019 | $170.02M | +15.9% |
| Q3 FY2019 | Sep 30, 2019 | $153.84M | +10.0% |
| Q2 FY2019 | Jun 30, 2019 | $148.71M | +11.2% |
| Q1 FY2019 | Mar 31, 2019 | $134.91M | +4.6% |
| Q4 FY2018 | Dec 31, 2018 | $146.63M | +23.4% |
| Q3 FY2018 | Sep 30, 2018 | $139.79M | +29.8% |
| Q2 FY2018 | Jun 30, 2018 | $133.75M | +20.2% |
| Q1 FY2018 | Mar 31, 2018 | $128.95M | -0.5% |
| Q4 FY2017 | Dec 31, 2017 | $118.79M | -22.5% |
| Q3 FY2017 | Sep 30, 2017 | $107.71M | – |
| Q2 FY2017 | Jun 30, 2017 | $111.31M | – |
| Q1 FY2017 | Mar 31, 2017 | $129.66M | – |
| Q4 FY2016 | Dec 31, 2016 | $153.32M | – |
See a number that looks wrong?